Spero Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2013)

Organization Overview

First Clinical Trial
2016
NCT03022175
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Spero Therapeutics | Spero Therapeutics Inc | Spero Therapeutics, Inc.